Presentation is loading. Please wait.

Presentation is loading. Please wait.

Kaplan-Meier survival plot for primary endpoint of arthritis development. Kaplan-Meier survival plot for primary endpoint of arthritis development. Arthritis-free.

Published byRafe Robinson Modified over 5 years ago

Similar presentations

Presentation on theme: "Kaplan-Meier survival plot for primary endpoint of arthritis development. Kaplan-Meier survival plot for primary endpoint of arthritis development. Arthritis-free."— Presentation transcript:

1 Kaplan-Meier survival plot for primary endpoint of arthritis development.
Kaplan-Meier survival plot for primary endpoint of arthritis development. Arthritis-free survival (%) depicted over time in months. At the 25th percentile, a difference of 12 months between the group receiving placebo (blue) versus rituximab (red) was observed (black horizontal line). The number of individuals at risk in each group at every follow-up time point is shown below the graph, follow-up was discontinued after development of arthritis. Danielle M Gerlag et al. Ann Rheum Dis 2019;78: ©2019 by BMJ Publishing Group Ltd and European League Against Rheumatism

Download ppt "Kaplan-Meier survival plot for primary endpoint of arthritis development. Kaplan-Meier survival plot for primary endpoint of arthritis development. Arthritis-free."

Similar presentations

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.

 Kaplan-Meier survival curves by frequency of exacerbations in patients with COPD: group A, patients with no acute exacerbations of COPD; group B, patients.
Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.

Algorithm based on the 2016 European League Against Rheumatism (EULAR) recommendations on rheumatoid arthritis (RA) management. Algorithm based on the.
The GR dimer in stromal cells mediates the induction of genes of anti-inflammatory macrophages after DEX treatment in serum transfer-induced arthritis.

The GR dimer in stromal cells mediates the induction of genes of anti-inflammatory macrophages after DEX treatment in serum transfer-induced arthritis.
Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)
(A) Lequesne index and quadriceps strength of patients with knee OA

(A) Lequesne index and quadriceps strength of patients with knee OA
Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.

Management of hyperuricaemia in patients with gout according to the European League Against Rheumatism recommendations. Management of hyperuricaemia in.
Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.

Kaplan-Meier survival plots for survival without: (A) progression to RA according to the number of joints with significant synovitis defined by GS≥ grade.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)

Efficacy end points: the percentage of patients achieving an improvement in American College of Rheumatology (ACR) of (A) 20% (ACR20), (B) 50% (ACR50)
Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.

Kaplan-Meier curves comparing: (A) overall survival for patients treated on trial compared to those outside of a trial; (B) progression-free survival for.
Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.

Long-term results estimates for patients with anomalous origin of coronary artery from the pulmonary artery, showing survival, freedom from coronary and.
Kaplan-Meier survival curve for unloader brace—Kaplan-Meier survival analysis demonstrated rapid conversion to TKR for the first 12 months, which then.

Kaplan-Meier survival curve for unloader brace—Kaplan-Meier survival analysis demonstrated rapid conversion to TKR for the first 12 months, which then.
Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.

Kaplan-Meier survival curves for the development of diabetes by quartiles of baseline pedometer steps. Kaplan-Meier survival curves for the development.
Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.

Risk of having any adverse effects with supplements compared with placebo. Risk of having any adverse effects with supplements compared with placebo. Stratified.
Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.

Kaplan-Meier-estimated PFS and OS are presented, with PFS in c-Met high and low patients shown in (A), OS in c-Met high and low patients in (B), PFS in.
Properties of leucocyte subset-specific type 1 interferon (IFN-1) modules. Properties of leucocyte subset-specific type 1 interferon (IFN-1) modules. (A)

Properties of leucocyte subset-specific type 1 interferon (IFN-1) modules. Properties of leucocyte subset-specific type 1 interferon (IFN-1) modules. (A)
Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.

Algorithm based on the ASAS-EULAR recommendations for the management of axial spondyloarthritis. Algorithm based on the ASAS-EULAR recommendations for.
Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.

Clinical expertise of GPs and rheumatologists in differentiating patients with arthralgia. Clinical expertise of GPs and rheumatologists in differentiating.
Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.

Step-down efficacy through week 48: categorical CDAI state DMARD-IR (RA-BEAM, RA-BUILD, RA-BEACON) analysis set. Step-down efficacy through week 48: categorical.
Coronal section through the distal interphalangeal joint of the left middle finger shown in figure 2. Coronal section through the distal interphalangeal.

Coronal section through the distal interphalangeal joint of the left middle finger shown in figure 2. Coronal section through the distal interphalangeal.

Similar presentations

Ads by Google